Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-12-10
2002-09-03
Geist, Gary (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C536S027800
Reexamination Certificate
active
06444652
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention is in the area of methods for the treatment of hepatitis B virus (also referred to as “HBV”) that includes administering to a host in need thereof, either alone or in combination, an effective amount of one or more of the active compounds disclosed herein, or a pharmaceutically acceptable prodrug or salt of one of these compounds.
HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown, although it is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.
Hepatitis B virus has reached epidemic levels worldwide. After a two to six month incubation period in which the host is unaware of the infection, HBV infection can lead to acute hepatitis and liver damage, that causes abdominal pain, jaundice, and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which massive sections of the liver are destroyed.
Patients typically recover from acute hepatitis. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
In western industrialized countries, high risk groups for HBV infection include those in contact with HBV carriers or their blood samples. The epidemiology of HBV is very similar to that of acquired immune deficiency syndrome (AIDS), which accounts for why HBV infection is common among patients with AIDS or AIDS related complex. However, HBV is more contagious than HIV.
However, more recently, vaccines have also been produced through genetic engineering and are currently used widely. Unfortunately, vaccines cannot help those already infected with HBV. Daily treatments with &agr;-interferon, a genetically engineered protein, has also shown promise, but this therapy is only successful in about one third of treated patients. Further, interferon cannot be given orally.
A number of synthetic nucleosides have been identified which exhibit activity against HBV. The (−)-enantiomer of BCH-189, known as 3TC, claimed in U.S. Pat. No. 5,539,116 to Liotta, et al., has been approved by the U.S. Food and Drug Administration for the treatment of hepatitis B. See also EPA 0 494 119 A1 filed by BioChem Pharma, Inc.
Cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (“FTC”) exhibits activity against HBV. See WO 92/15308; Furman, et al., “The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine”
Antimicrobial Agents and Chemotherapy
, December 1992, 5page 2686-2692; and Cheng, et al.,
Journal of Biological Chemistry,
Volume 267(20), 13938-13942 (1992).
von Janta-Lipinski et al. disclose the use of the L-enantiomers of 3′-fluoro-modified &bgr;-2′-deoxyribonucleoside 5′-triphosphates for the inhibition of hepatitis B polymerases (J. Med. Chem., 1998, 41,2040-2046). Specifically, the 5′-triphosphates of 3′-deoxy-3′-fluoro-&bgr;-L-thymidine (&bgr;-L-FTTP), 2′,3′-dideoxy-3′-fluoro-&bgr;-L-cytidine (&bgr;-L-FdCTP), and 2′,3′-dideoxy-3′-fluoro-&bgr;-L-5-methylcytidine (&bgr;-L-FMethCTP) were disclosed as effective inhibitors of HBV DNA polymerases.
WO 96/13512 to Genencor International, Inc. and Lipitek, Inc. discloses that certain L-ribofuranosyl nucleosides can be useful for the treatment of cancer and viruses. Specifically disclosed is the use of this class of compounds for the treatment of cancer and HIV.
U.S. Pat. Nos. 5,565,438, 5,567,688 and 5,587,362 (Chu, et al.) disclose the use of 2′-fluoro-5-methyl-&bgr;-L-arabinofuranolyluridine (L-FMAU) for the treatment of hepatitis B and Epstein Barr virus.
Yale University and University of Georgia Research Foundation, Inc. disclose the use of L-FddC (&bgr;-L-5-fluoro-2′,3′-dideoxycytidine) for the treatment of hepatitis B virus in WO 92/18517.
The synthetic nucleosides &bgr;-L-2′-deoxycytidine (&bgr;-L-2′-dC), &bgr;-L-2′-deoxythymidine (&bgr;-L-dT) and &bgr;-L-2′-deoxyadenosine (&bgr;-L-2′-dA), are known in the art. Antonin Holy first disclosed &bgr;-L-dC and &bgr;-L-dT in 1972, “Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2′-deoxy-L-Ribonucleosides of the Pyrimidine Series,”
Collect. Czech. Chem. Commun.
(1972), 37(12), 4072-87. Morris S. Zedeck et al. first disclosed &bgr;-L-dA for the inhibition of the synthesis of induced enzymes in
Pseudomonas testosteroni, Mol. Phys.
(1967), 3(4), 386-95.
Certain 2′-deoxy-&bgr;-L-erythro-pentofuranonucleosides are known to have antineoplastic and selected antiviral activities. Verri et al. disclose the use of 2′-deoxy-&bgr;-L-erythro-pentofuranonucleosides as antineoplastic agents and as anti-herpetic agents (
Mol. Pharmacol.
(1997), 51(1), 132-138 and
Biochem. J.
(1997), 328(1), 317-20). Saneyoshi et al. demonstrate the use of 2′-deoxy-L-ribonucleosides as reverse transcriptase (I) inhibitors for the control of retroviruses and for the treatment of AIDS, Jpn. Kokai Tokkyo Koho JP06293645 (1994).
Giovanni et al. tested 2′-deoxy-&bgr;-L-erythro-pentofuranonucleosides against partially pseudorabies virus (PRV),
Biochem. J.
(1993), 294(2), 381-5.
Chemotherapeutic uses of 2′-deoxy-&bgr;-L-erythro-pentofuranonucleosides were studied by Tyrsted et al. (
Biochim. Biophys. Acta
(1968), 155(2), 619-22) and Bloch, et al. (
J. Med. Chem.
(1967), 10(5), 908-12).
&bgr;-L-2′-deoxythymidine (&bgr;-L-dT) is known in the art to inhibit herpes simplex virus type 1 (HSV-1) thymidine kinase (TK). Iotti et al., WO 92/08727, teaches that &bgr;-L-dT selectively inhibits the phosphorylation of D-thymidine by HSV-1 TK, but not by human TK. Spaldari et al. reported that L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth,
J. Med. Chem.
(1992), 35(22), 4214-20.
In light of the fact that hepatitis B virus has reached epidemic levels worldwide, and has severe and often tragic effects on the infected patient, there remains a strong need to provide new effective pharmaceutical agents to treat humans infected with the virus that have low toxicity to the host.
Therefore, it is an object of the present invention to provide new methods and compositions for the treatment of human patients or other hosts infected with hepatitis B virus.
SUMMARY OF THE INVENTION
A method for the treatment of hepatitis B infection in humans and other host animals is disclosed that includes administering an effective amount of a biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside (referred to alternatively herein as a &bgr;-L-d-nucleoside or a &bgr;-L-2′-d-nucleoside) or a pharmaceutically acceptable salt or prodrug thereof, administered either alone or in combination, optionally in a pharmaceutically acceptable carrier. The term 2′-deoxy, as used in this specification, refers to a nucleoside that has no substituent in the 2′-position.
The disclosed 2′-deoxy-&bgr;-L-erythro-pentofuranonucleosides, or pharmaceutically acceptable prodrugs or salts or pharmaceutically acceptable formulations containing these compounds are useful in the prevention and treatment of hepatitis B infections and other related conditions such as anti-HBV antibody positive and HBV-positive conditions, chronic liver inflammation caused by HBV, cirrhosis,
Bryant Martin L.
Gosselin Gilles
Imbach Jean-Louis
Crane L. Eric
Geist Gary
King & Spalding
Knowles, Esq. Sherry M.
Novirio Pharmaceuticals Limited
LandOfFree
&bgr;-L-2'-deoxy-nucleosides for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with &bgr;-L-2'-deoxy-nucleosides for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and &bgr;-L-2'-deoxy-nucleosides for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2878088